patient	normal.sample	tumor.sample	purity	time.point  date
01-007	007-BF	01-2-007-4	85.5	post	8/31/2014
01-009	009-BF	01-1-009-1	90	pre	8/13/2010
01-010	010-BF	01-1-010-1	90	pre	9/20/2010
01-010	010-BF	01-2-010-1	80	post	4/5/2011
01-013	013-BF	01-1-013-1	100	pre	10/13/2010
01-014	014-BF	01-1-014-2	51	pre	11/1/2010
01-014	014-BF	01-2-014-1	76.5	post	9/19/2012
01-015	015-BF	01-1-015-1	70	pre	11/8/2010
01-021	021-BF	01-1-021-2	66.5	pre	4/6/2011
01-021	021-BF	01-2-021-1	66.5	post	6/15/2012
01-021	021-BF	01-3-021-1	20	post	11/1/2012
01-027	027-BF	01-1-027-2	57	pre	8/18/2011
01-029	029-BF	01-1-029-2	80	pre	8/26/2011
01-029	029-BF	01-2-029-4	85	post	1/16/2012
01-029	029-BF	01-2-029-2	54	post	1/16/2012
01-040	040-BF	01-1-040-1	65	pre	1/18/2012
01-043	043-BF	01-1-043-2	90	pre	4/18/2012
01-045	045-BF	01-1-045-1	80	pre	4/23/2012
01-046	046-WB	01-1-046-2	70	pre	4/24/2012
01-048	048-BF	01-1-048-1	37.5	pre	12/12/2012
01-049	049-BF	01-2-049-14	30	post	3/14/2013
01-049	049-BF	01-2-049-17	56	post	3/14/2013
01-049	049-BF	01-2-049-1	95	post	3/14/2013
01-049	049-BF	01-2-049-6	75	post	3/14/2013
01-049	049-BF	01-2-049-9	80	post	3/14/2013
01-049	049-BF	01-2-049-26	80	post	NA
01-049	049-BF	01-1-049-1	35	pre	9/20/2012
01-050	050-BF	01-1-050-FFPE	60	pre	10/24/2012
01-050	050-BF	01-2-050-1	63	post	NA
cell-line	NA	HT29	100	pre	NA
cell-line	NA	R3	100	post	NA
